Crinetics Pharmaceuticals Inc
Lezárt
SzektorEgészségügy
84.95 0.13
Áttekintés
Árfolyamváltozás megosztása
24 óra
Minimum
84.95
Maximum
84.95
Bevétel | 7M -121M |
|---|---|
Értékesítés | 14M 25M |
Egy részvényre jutó nyereség | -1.14 |
Profit margin | -481.149 |
Munkavállalók | 594 |
EBITDA | -4.7M -131M |
Ajánlások | Semleges |
|---|---|
12 hónapos előrejelzés | +0.72% upside |
Piaci kapitalizáció | 148M 9B |
|---|---|
Előző nyitás | 84.82 |
Előző zárás | 84.95 |
Crinetics Pharmaceuticals Inc Chart
A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.
Kapcsolódó hírek
Társak összehasonlítása
Árváltozás
Crinetics Pharmaceuticals Inc Előrejelzés
Célár
By TipRanks
0.72% elmozdulás felfelé
12 hónapos előrejelzés
Átlag 85.56 USD 0.72%
Magas 95 USD
Alacsony 80 USD
11 Wall Street elemző 12 hónapos célárain alapulva a(z)Crinetics Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.
Pénzügyek
$
Rólunk Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.